Participants were randomly assigned to receive either dapagliflozin 10 mg daily or placebo for 12 months. Patients were ...

India accounts for 1 in 7 adults living with diabetes globally. An estimated 89.8 million adults aged 20-79 years in India ...

A new clinical trial shows that combining dapagliflozin with insulin improves kidney health and blood sugar control, and ...

On 21 July 2025, the Court of Appeal delivered a significant ruling in AstraZeneca AB & Anor v Generics (UK) Limited & Ors, ...

Combining insulin treatment with the investigational drug dapagliflozin may improve health outcomes for adolescents with type ...

Combining insulin treatment with the investigational drug dapagliflozin may improve health outcomes for adolescents with type 1 diabetes, according to ...

No increased risk of thrombotic events identified despite rise in erythrocytosis among sodium-glucose cotransporter 2 ...

The majority of patients with heart failure who qualified for sodium-glucose cotransporter 2 inhibitor (SGLT2i) therapy did ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

Researchers have found in a new research that SGLT2 inhibitors may provide dual benefits in treating both diabetes and fatty ...

The new label for Forxiga/Farxiga (dapagliflozin) comes from the DECLARE-TIMI 58 trial, and the EU is the first major market to approve the label update, ahead of the US and China where it remains ...

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.